Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
STA Pharmaceutical
STA Pharmaceutical
X
LinkedIn
Trending Articles
Wacker Biotech to manufacture protein ingredients for MinervaX's late-stage GBS vaccine
The vaccine is currently being prepared for Phase III trials, and aims to protect mothers and their babies from group B streptococcus infections
Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer
The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
AstraZeneca opens a 'people hub' at its Macclesfield site
The energy-efficient building will offer AZ employees a collaborative space
Ensuring cGMP compliance in cell and gene therapy manufacturing
3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
Piramal Pharma's sustainability goals get SBTi-validated
The company wants to reduce its scope 1 and 2 GHG emissions by 42% by 2030, and is also working on developing a carbon reduction plan
Upcoming event
Boston Biotech Week
23-26 September, 2024 | Convention and exhibition | Boston, US
See all
Related Content
Research & Development
Manufacturing Chemist Live: Day One Review
The first day of MC Live has now concluded, with attendees enjoying presentations from STA Pharmaceuticals, NSF International and Lonza, among others
Manufacturing
Process optimisation with biocatalysis
From route scouting, screening and scale-up to commercial production, Dr Jingyang Zhu, VP Process Chemistry Enabling Technologies at WuXi, discusses the services and capabilities of a modern CDMO
Manufacturing
Process optimisation with flow chemistry
WuXi STA, the Chinese CDMO with a global footprint, embraces the need to develop drugs for customers using safer, more cost-effective technologies and expedite their time to market
Drug Delivery
BioLingus partnership boosts WuXi STA’s solid dose potential
The collaboration will use BioLingus' technology to focus on sublingual and buccal drug delivery
Subscribe now